Atle Fund Management AB Has $14.41 Million Position in Neurocrine Biosciences, Inc. $NBIX

Atle Fund Management AB boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 16.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,625 shares of the company’s stock after acquiring an additional 14,233 shares during the quarter. Neurocrine Biosciences accounts for 5.6% of Atle Fund Management AB’s portfolio, making the stock its 3rd largest position. Atle Fund Management AB owned approximately 0.10% of Neurocrine Biosciences worth $14,406,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NBIX. Vanguard Personalized Indexing Management LLC raised its stake in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock valued at $1,560,000 after purchasing an additional 77 shares during the period. Diametric Capital LP raised its position in Neurocrine Biosciences by 2.6% in the 2nd quarter. Diametric Capital LP now owns 3,244 shares of the company’s stock valued at $408,000 after buying an additional 81 shares during the last quarter. Great Lakes Advisors LLC lifted its stake in Neurocrine Biosciences by 2.4% in the 3rd quarter. Great Lakes Advisors LLC now owns 3,605 shares of the company’s stock valued at $506,000 after acquiring an additional 84 shares in the last quarter. IFP Advisors Inc boosted its position in Neurocrine Biosciences by 4.2% during the 2nd quarter. IFP Advisors Inc now owns 2,172 shares of the company’s stock worth $273,000 after acquiring an additional 88 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC grew its stake in shares of Neurocrine Biosciences by 1.5% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 6,699 shares of the company’s stock worth $842,000 after acquiring an additional 96 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on NBIX shares. Wall Street Zen lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday. HC Wainwright upped their target price on Neurocrine Biosciences from $168.00 to $198.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. JPMorgan Chase & Co. decreased their price target on Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Monday, January 12th. Stifel Nicolaus boosted their price target on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $175.00 price objective (up previously from $173.00) on shares of Neurocrine Biosciences in a report on Thursday, January 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $174.25.

Neurocrine Biosciences Stock Performance

NBIX opened at $136.06 on Friday. The stock has a fifty day moving average of $143.13 and a 200-day moving average of $140.26. The company has a market capitalization of $13.57 billion, a P/E ratio of 32.55, a P/E/G ratio of 0.73 and a beta of 0.28. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $160.18.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director George J. Morrow sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total value of $2,150,550.00. Following the completion of the sale, the director owned 7,068 shares of the company’s stock, valued at $1,013,339.16. The trade was a 67.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kyle Gano sold 36,400 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the transaction, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 80,266 shares of company stock worth $11,400,517. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.